Last reviewed · How we verify

Topiramate-Implant

University of Sao Paulo · FDA-approved active Small molecule

Topiramate is a sulfamate-substituted monosaccharide that enhances GABA-mediated inhibition and blocks sodium channels to reduce neuronal excitability.

Topiramate is a sulfamate-substituted monosaccharide that enhances GABA-mediated inhibition and blocks sodium channels to reduce neuronal excitability. Used for Epilepsy / seizure prevention, Migraine prophylaxis.

At a glance

Generic nameTopiramate-Implant
SponsorUniversity of Sao Paulo
Drug classAnticonvulsant / Antiepileptic agent
TargetGABA-A receptor, sodium channels, glutamate receptors
ModalitySmall molecule
Therapeutic areaNeurology
PhaseFDA-approved

Mechanism of action

Topiramate potentiates the activity of the inhibitory neurotransmitter GABA at GABA-A receptors and antagonizes excitatory glutamate receptors, while also blocking voltage-gated sodium channels. When formulated as an implant, it provides sustained local or systemic drug delivery to maintain therapeutic levels over an extended period. This mechanism reduces abnormal neuronal firing and is used to prevent seizures and manage other neurological conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: